Daré Bioscience (NASDAQ:DARE) Stock Crosses Below 200 Day Moving Average – Should You Sell?

Daré Bioscience, Inc. (NASDAQ:DARE) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.65 and traded as low as $3.18. Daré Bioscience shares last traded at $3.20, with a volume of 23,719 shares.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a report on Tuesday, December 17th.

Daré Bioscience Stock Up 2.2 %

The firm’s fifty day moving average is $3.51 and its two-hundred day moving average is $3.62. The firm has a market cap of $28.45 million, a P/E ratio of -5.54 and a beta of 1.27.

Institutional Investors Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC boosted its stake in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the period. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. 6.70% of the stock is currently owned by institutional investors.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.